Omeros scores its first-ever FDA nod as stem cell transplant drug Yartemlea approved

26th December 2025 Uncategorised 0

With a Christmas Eve thumbs up for Yartemlea, the FDA has delivered Omeros its first U.S. approval in its 31 years. Yartemlea becomes the first treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy.

More: Omeros scores its first-ever FDA nod as stem cell transplant drug Yartemlea approved
Source: fierce